Incivek Articles
First interferon-free regimens for hepatitis C virus expected to launch in 2014 in the USA and Europe
20 December 2012
Uptake of Peg-IFN agents for HCV in China and South Korea hindered by relatively high cost and their partial reimbursement status
21 October 2012
Incivek and Victrelis have collectively penetrated over three-quarters of the US genotype 1 HCV market
7 June 2012
Germany’s IQWiG sees added benefits for Incivo
24 January 2012
Vertex plans for Kalydeco launch
9 January 2012
Vertex’ Incivek set to break record for fastest product launch
8 November 2011
Hepatitis C landscape changing as the new protease inhibitors adopted into clinical practice
9 October 2011
Johnson & Johnson’s telaprevir approved in Europe for genotype-1 chronic hepatitis C
21 September 2011
Europe’s CHMP adopts positive opinions on Dexdor, Incivo, Plenadren, Vyndaqel and Zytiga; backs extensions
23 July 2011
Most US clinicians plan to prescribe Incivek and Victrelis for treatment-naive hep C patients
5 July 2011
Showing 1-18 of 18 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
